Sanbio has initiated a Phase I/IIa study of SB623 in chronic, stable stroke patients. This study is listed on the Clinical Trials website where additional details about the study are provided: www.clinicaltrials.gov/sb623
When injected into neural tissue, SB623 reverses neural damage. Since SB623 cells are allogeneic, a single donor's cells can be used to treat thousands of patients. In cell culture and animal models, SB623 cells have been shown to restore function to damaged neurons associated with stroke, spinal cord injury and Parkinson's disease. The Company believes SB623 may also be useful in other diseases and conditions associated with neurological deficit, such as traumatic brain injury, Huntington's disease and amyotrophic lateral sclerosis. SB623 cells function by promoting the body's natural regenerative process. SB623 is in the early clinical stage of development for stroke.
SanBio is developing SB618 for the treatment of conditions that affect the myelin sheath of neurons such as multiple sclerosis and spinal cord injury. The myelin sheath serves as insulation for the long axons of nerve cells allowing for the rapid transmission of signals along the nerve. Loss of the myelin sheath can result in debilitating symptoms such as dyskinesia, loss of motor function and death. Like SB623, SB618 cells are allogeneic, a single donor's cells can be used to treat thousands of patients.
SanBio has extended its core technology beyond the nervous system. A similar approach has been used to develop SB308 which uses donor bone marrow to stimulate muscle regeneration. The Company believes that SB308 can be used to treat conditions such as muscular dystrophy and in recovery from trauma and surgery. This technology has been tested in a rat model of muscle degeneration with positive results.